Grad Zagreb

• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease
• Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting
  2023-504724-25-00 5 2024-10-16 Primary Myelofibrosis
• 202301CPC Redefine-HF Recruiting
  2023-508581-15-00 5 2024-10-08 Heart condition
• A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10 … Recruiting
  2023-507353-15-00 5 2024-09-10 idiopathic pulmonary fibrosis (IPF)
• Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) Recruiting
  2023-507692-21-00 3 2024-08-22 Antiphospholipid syndrome
• A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-508158-24-00 4 2024-06-25 Moderately to Severely Active Crohn’s Disease
• A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting
  2023-506150-21-00 4 2024-05-29 Celiac Disease
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL … Recruiting
  2023-507871-23-00 5 2024-05-27 Relapsed/Refractory Multiple Myeloma
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w … Recruiting
  2023-504151-27-00 5 2024-05-09 Psychosis associated with Alzheimer’s Disease
• Phase 3 study to assess the efficacy and safety of Givinostat versus hydroxyurea in Polycythemia Vera patients Recruiting
  2022-502276-23-00 5 2024-04-25 JAK2V617F-positive high-risk Polycythemia Vera
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• An Open-label Study of XEN1101 in Epilepsy Recruiting
  2022-502282-24-00 5 2024-02-14 Primary generalized tonic-clonic seizures
• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab … Recruiting
  2023-503224-66-00 5 2023-10-31 Atrial Fibrillation
• Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting
  2023-503661-28-00 5 2023-10-26 Hidradenitis Suppurativa
• Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis study (NuPOWER) Recruiting
  2022-502060-21-00 6 2023-10-19 Haemophilia A
• Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Recruiting
  2022-502281-25-00 5 2023-09-27 Focal Onset Seizures
• A Long-term Study in Children and Teenagers with Ulcerative Colitis or Crohn’s Disease treated with Vedolizumab IV Recruiting
  2023-509046-36-00 5 2023-04-26 Active Ulcerative Colitis (UC) or Crohn's disease (CD)
• Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors Recruiting
  2022-500470-33-00 5 2022-11-14 Haemophilia
• Research study to assess the potential of masupirdine in patients with agitation symptoms associated with memory loss Recruiting
  2024-513835-25-00 5 2022-10-27 Agitation with Dementia of the Alzheimer's Type
• A study of Vedulizumab in Children and Teenagers with Moderate to Severe Crohn's Disease (CD) Recruiting
  2023-509045-13-00 5 2022-02-28 Moderately to severely active Crohn's disease (CD)
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• Weight loss in people living with overweight or obesity and type 2 diabetes following treatment with cagrilintide Ended recruitment
  2024-519531-41-00 5 2025-10-31 Overweight and obesity
• A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 … Ended recruitment
  2024-512914-16-00 5 2025-09-12 Relapsing-remitting Multiple Sclerosis

Showing 73–96 of 207 trials